| Literature DB >> 21492424 |
Gregor Prosen1, Petra Klemen, Matej Štrnad, Stefek Grmec.
Abstract
INTRODUCTION: We studied the diagnostic accuracy of bedside lung ultrasound (the presence of a comet-tail sign), N-terminal pro-brain natriuretic peptide (NT-proBNP) and clinical assessment (according to the modified Boston criteria) in differentiating heart failure (HF)-related acute dyspnea from pulmonary (chronic obstructive pulmonary disease (COPD)/asthma)-related acute dyspnea in the prehospital setting.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21492424 PMCID: PMC3219397 DOI: 10.1186/cc10140
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Flow diagram illustrating recruitment, exclusion and subsequent grouping of all patients in the study. NT-proBNP, N-terminal pro-brain natriuretic peptide.
Study protocol for prehospital clinical assessment of HF (modified Boston criteria)a
| Criterion | Point valueb | |
|---|---|---|
| Category I: History | Rest dyspnea | 4 |
| Orthopnea | 4 | |
| Paroxysmal nocturnal dyspnea | 3 | |
| Dyspnea while walking on level area | 2 | |
| Dyspnea while climbing | 1 | |
| Category II: Physical examination | Heart rate abnormality (1 point if 91 to 110 beats/minute; | 1 or 2 |
| Jugular venous elevation (2 points if greater than 5 cmH2O; | 2 or 3 | |
| Lung rales (1 point if basilar; 2 points if more than basilar) | 1 or 2 | |
| Wheezing | 3 | |
| Third heart sound | 3 | |
| Category III: Additional | Hepatojugular reflux | 1 |
| ECG changes (HLV, old AMI or nonspecific ST-T changes, arrhythmia) | 1 | |
| Night cough | 1 | |
| Murmur | 1 | |
| Without sputum and/or fever | 1 | |
| Previous AMI, arrhythmia or HF | 1 | |
| HF medications | 1 | |
aBoston criteria [6]. HF, heart failure; ECG, electrocardiogram; HLV, hypertrophy of the left ventricle; AMI, acute myocardial infarction. bPoint value: no more than 4 points allowed from each of three categories; hence the composite score (sum of the subtotal from each category) has a possible maximum of 12 points. The diagnosis of heart failure is classified as "definite" at a score 8 to 12 points, "possible" at a score 5 to 7 points and "unlikely" at a score of 4 points or less.
Univariate analysis for all demographic and clinical variables pertinent to diagnosis of acute HF or pulmonary disease (N = 218)a
| Variablesb | Pulmonary-related dyspnea ( | Acute HF-related dyspnea ( | |
|---|---|---|---|
| Mean age, yr (± SD) | 52.3 ± 15.3 | 70.9 ± 11.7 | 0.001 |
| Sex, males/females (%) | 176/87 (67%) | 1,158/421 (73%) | 0.74 |
| Nocturnal dyspnea, Y/N | 6/83 | 1/2 | < 0.001 |
| Orthopnea, Y/N | 7/82 | 13/30 | < 0.001 |
| Cough, Y/N | 17/41 | 34/95 | < 0.001 |
| Sputum production, Y/N | 24/65 | 8/121 | < 0.001 |
| Fever, Y/N | 21/68 | 7/122 | < 0.001 |
| Murmur, Y/N | 8/81 | 29/100 | < 0.001 |
| Rales, Y/N | 10/79 | 217/53 | < 0.001 |
| Wheezes, Y/N | 12/3 | 47/82 | < 0.001 |
| Mean pulse rate, beats/min (± SD) | 115.7 ± 14.1 | 106.3 ± 12.8 | 0.564 |
| Jugular venous distension, Y/N | 3/86 | 10/33 | < 0.001 |
| Lower extremity edema, Y/N | 12/77 | 62/67 | < 0.001 |
| ECG-normal sinus rhythm, Y/N | 210/17 | 55/72 | < 0.001 |
| Asthma/COPD medications, Y/N | 65/11 | 13/116 | < 0.001 |
| HF medications, Y/N | 33/56 | 245/46 | < 0.001 |
| Troponin T > 0.03 ng/mL, Y/N | 8/81 | 49/80 | < 0.001 |
| Mean petCO2, kPa (± SD) | 6.9 ± 1.6 | 3.6 ± 1.1 | 0.01 |
| Mean NT-proBNP, pg/mL (± SD) | 598.2 ± 361.8 | 2,263 ± 641.2 | 0.008 |
| Mean SaO2, % (± SD) | 75.7 ± 10.1 | 67.9 ± 12.8 | 0.76 |
| Ultrasound examination-positive, Y/N | 5/84 | 129/0 | < 0.001 |
| Previous arrhythmia, Y/N | 7/82 | 52/77 | < 0.001 |
| Previous AMI, Y/N | 7/82 | 15/28 | < 0.001 |
| Previous CHF, Y/N | 17/72 | 233/49 | < 0.001 |
| Previous asthma/COPD, Y/N | 169/19 | 9/34 | < 0.001 |
| ETI, Y/N | 3/86 | 10/119 | < 0.001 |
| Mean modified Boston criteria score for diagnosing HFd (± SD) | 4.6 ± 1.2 | 10.9 ± 1.8 | < 0.001 |
aY, yes; N, no; petCO2, partial pressure of end-tidal carbon dioxide; NT-proBNP, amino terminal pro-brain natriuretic peptide; ECG, electrocardiogram; HF, heart failure; CHF, congestive heart failure; AMI, acute myocardial infarction; SaO2, arterial oxygen saturation; ETI, endotracheal intubation; COPD, chronic obstructive pulmonary disease. bResults are presented as means ± standard deviation for normally distributed data or ratio or percentage for other variables. cUnivariate comparison was made using the χ2 test for categorical variables and a t-test for continuous variables. For evaluation of diagnostic accuracy, patients were divided into two groups: HF-related acute dyspnea and pulmonary-related acute dyspnea (COPD/asthma). dModified Boston criteria according to Table 1 and Remes et al. [6].
Multiple logistic regression analysis of factors used for differentiation between HF-related and pulmonary-related acute dyspnea in prehospital emergency settinga
| Factor | OR (95% CI)b | |
|---|---|---|
| Ultrasound examination | 53.7 (28.6 to 83.5) | < 0.001 |
| NT-proBNP | 14.3 (8.1 to 29.4) | < 0.001 |
| Orthopnea | 6.9 (1.9 to 18.39 | < 0.001 |
| Rales | 5.1 (1.5 to 12.8) | 0.014 |
| Troponin T | 2.1 (1.3 to 4.6) | 0.018 |
| petCO2 | 7.6 (2.9 to 19.6) | < 0.001 |
| HF medications | 2.7 (1.3 to 5.1) | 0.031 |
| Asthma/COPD medications | 0.12 (0.03 to 0.42) | 0.028 |
| Previous HF | 7.4 (2.3 to 20.4) | < 0.001 |
| Fever | 0.17 (0.06 to 0.49) | 0.017 |
aOR, odds ratio; petCO2, partial pressure of end-tidal carbon dioxide; NT-proBNP, amino terminal pro-brain natriuretic peptide; HF, heart failure; COPD, chronic obstructive pulmonary disease; CI, confidence interval. bUnivariable screening was performed on clinical, historical and biochemical variables to identify potential predictors of HF. Odds ratios for the presence of HF were generated and expressed with 95% CI. cMultivariable analysis with logistic regression was used to identify potential predictor variables of a final diagnosis of HF (variables from univariate analysis with P < 0.05 for entry into model).
Test characteristics of ultrasound examination, modified Boston examination, NT-proBNP and combination of ultrasound examination and NT-proBNPa
| Characteristic | Ultrasound examinationb | Modified Boston criteria scoring | NT-proBNP | Ultrasound examination + NT-proBNPc | |
|---|---|---|---|---|---|
| Sensitivity | 100% | 85% | 92% | 100% | < 0.01 |
| Specificity | 95% | 86% | 89% | 100% | < 0.01 |
| NPV | 100% | 80% | 86% | 100% | < 0.01 |
| PPV | 96% | 90% | 90% | 100% | < 0.01 |
| LR+ | 20 | 6.1 | 8.36 | Infinite | < 0.01 |
| LR- | 0 | 0.18 | 0.09 | 0 | < 0.01 |
| AUROC | 0.94 | 0.86 | 0.90 | 0.99 | < 0.01 |
aNPV, negative predictive value; PPV, positive predictive value; LR+, positive likelihood ratio; LR-, negative likelihood ratio; AUROC, area under receiver-operating curve; NT-proBNP, amino terminal pro-brain natriuretic peptide; UE, ultrasound examination. bUE alone was statistically significantly more accurate in diagnosing HF than the modified Boston criteria and NT-proBNP (better sensitivity, specificity, NPV, PPV, LR+, LR- and AUROC; P < 0.01). cThe combination of UE and NT-proBNP was the supreme method in diagnosing HF in a prehospital setting; when compared with UE alone, it had equal results in sensitivity, NPV and LR- (P = 0.99) and significantly better results in specificity, PPV and AUROC (P < 0.01). Compared with Boston modified criteria or NT-proBNP alone, UE + NT-proBNP was significantly better with regard to all characteristics (sensitivity, specificity, NPV, PPV, LR+, LR- and AUROC; P < 0.01). dThe comparison of the four methods was done using the χ2 test with the Bonferroni correction for multiple comparisons. The AUROC accuracy of UE (lung comet-tail sign); NT-proBNP; Boston criteria for diagnosing HF (clinical assessment); and the combination of ultrasound, NT-proBNP and Boston criteria were calculated and compared with univariate Z-score testing. AUROC was compared using the technique proposed by Hanley and Mc Neil [20] and Jannuzzi et al. [21].